| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 7.581 | 7.671 | 6.774 | 3.739 | 4.212 | 5.193 | 1.757 | 3.041 | 3.179 | 3.915 |
| Total Income - EUR | 7.593 | 7.694 | 7.619 | 5.057 | 6.057 | 6.166 | 3.477 | 3.754 | 3.212 | 3.915 |
| Total Expenses - EUR | 9.611 | 9.400 | 7.815 | 2.125 | 5.072 | 8.771 | 7.080 | 3.214 | 2.190 | 8.056 |
| Gross Profit/Loss - EUR | -2.018 | -1.706 | -196 | 2.932 | 986 | -2.606 | -3.602 | 540 | 1.022 | -4.141 |
| Net Profit/Loss - EUR | -2.249 | -1.859 | -297 | 2.781 | 858 | -2.662 | -3.620 | 461 | 859 | -4.141 |
| Employees | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 |
Check the financial reports for the company - Biomaterials Company S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 583 | 0 | 0 | 11 | 11 | 10 | 10 | 10 | 10 | 10 |
| Current Assets | 3.802 | 2.496 | 3.027 | 2.524 | 4.103 | 2.583 | 2.513 | 3.566 | 3.484 | 3.175 |
| Inventories | 1.724 | 662 | 119 | 438 | 2.147 | 1.502 | 1.545 | 1.814 | 1.647 | 1.362 |
| Receivables | 1.799 | 1.461 | 1.578 | 1.877 | 1.685 | 207 | 544 | 915 | 837 | 1.659 |
| Cash | 279 | 374 | 1.330 | 208 | 272 | 874 | 425 | 837 | 1.000 | 154 |
| Shareholders Funds | -12.147 | -13.883 | -13.944 | -10.907 | -9.838 | -12.313 | -15.660 | -15.248 | -14.343 | -18.403 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 16.532 | 16.379 | 16.971 | 13.441 | 13.952 | 14.906 | 18.183 | 18.824 | 17.837 | 21.588 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Biomaterials Company S.r.l.